United Therapeutics Corp expected to post earnings of $6.31 a share - Earnings Preview

United Therapeutics

24/02/2025 13:54

* United Therapeutics Corp  UTHR.OQ   UTHR.O  is expected
to show
a rise in quarterly revenue when it reports  results on February
26 for the period ending December 31 2024
    * The Silver Spring Maryland-based  company is expected to
report
a 19.5% increase in revenue to $734.74 million from $614.7
million a year ago, according to the mean estimate from 11
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for United Therapeutics Corp
is
for earnings of $6.31 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 5
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for United
Therapeutics Corp is $395.00​, above​ its last closing price
of $361.10. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  6.32        6.42       6.39      Missed  -0.5
 Jun. 30 2024  6.48        6.40       5.85      Missed  -8.6
 Mar. 31 2024  5.70        5.65       6.17      Beat    9.2​
 Dec. 31 2023  4.09        4.19       4.36      Beat    4.2
 ​​Sep.        5.04        5.04       5.38      Beat    6.7
 30 2023                                                
 Jun. 30 2023  4.49        4.51       5.24      Beat    16.3​
 Mar. 31 2023  4.41        4.52       4.86      Beat    7.4
 Dec. 31 2022  4.54        4.51       2.67      Missed  -40.8
 This summary was machine generated February 24 at 13:54 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)